Gofen & Glossberg LLC IL lowered its position in shares of Allergan plc (NYSE:AGN) by 11.6% during the fourth quarter, HoldingsChannel.com reports. The firm owned 77,583 shares of the company’s stock after selling 10,181 shares during the period. Gofen & Glossberg LLC IL’s holdings in Allergan were worth $12,691,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of AGN. Howard Hughes Medical Institute purchased a new stake in shares of Allergan during the second quarter valued at approximately $103,000. Cable Hill Partners LLC raised its stake in shares of Allergan by 255.2% during the third quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock valued at $106,000 after purchasing an additional 370 shares during the period. Rockefeller Financial Services Inc. raised its stake in shares of Allergan by 283.7% during the third quarter. Rockefeller Financial Services Inc. now owns 541 shares of the company’s stock valued at $111,000 after purchasing an additional 400 shares during the period. Massey Quick & Co. LLC raised its stake in shares of Allergan by 334.8% during the second quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock valued at $122,000 after purchasing an additional 385 shares during the period. Finally, Pacific Center for Financial Services raised its stake in shares of Allergan by 1.3% during the second quarter. Pacific Center for Financial Services now owns 541 shares of the company’s stock valued at $132,000 after purchasing an additional 7 shares during the period. Institutional investors own 81.26% of the company’s stock.

In other news, insider William Meury sold 11,807 shares of the business’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $173.89, for a total transaction of $2,053,119.23. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Brent L. Saunders purchased 4,600 shares of Allergan stock in a transaction dated Wednesday, December 6th. The shares were purchased at an average cost of $164.74 per share, with a total value of $757,804.00. The disclosure for this purchase can be found here. In the last three months, insiders have bought 17,630 shares of company stock valued at $2,890,057. Corporate insiders own 0.36% of the company’s stock.

A number of research firms have recently issued reports on AGN. Royal Bank of Canada reiterated an “outperform” rating and set a $250.00 price objective (down previously from $277.00) on shares of Allergan in a research note on Thursday, October 19th. They noted that the move was a valuation call. JPMorgan Chase & Co. set a $275.00 price objective on shares of Allergan and gave the company a “buy” rating in a research note on Sunday, October 22nd. Wells Fargo & Co set a $245.00 price target on shares of Allergan and gave the stock a “buy” rating in a research report on Friday, January 5th. Credit Suisse Group set a $214.00 price target on shares of Allergan and gave the stock a “buy” rating in a research report on Tuesday, December 19th. They noted that the move was a valuation call. Finally, Mizuho reissued a “buy” rating and set a $267.00 price target on shares of Allergan in a research report on Monday, September 25th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the company. Allergan currently has an average rating of “Hold” and an average target price of $226.95.

Allergan plc (NYSE AGN) opened at $176.05 on Tuesday. Allergan plc has a 1-year low of $160.07 and a 1-year high of $256.80. The stock has a market cap of $58,550.00, a price-to-earnings ratio of -7.79, a PEG ratio of 1.30 and a beta of 1.11. The company has a current ratio of 1.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.40.

Allergan (NYSE:AGN) last announced its quarterly earnings results on Wednesday, November 1st. The company reported $4.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.06 by $0.09. Allergan had a negative net margin of 47.27% and a positive return on equity of 8.00%. The company had revenue of $4.03 billion during the quarter, compared to the consensus estimate of $4.04 billion. During the same quarter in the previous year, the company posted $3.32 earnings per share. The company’s revenue for the quarter was up 11.4% compared to the same quarter last year. sell-side analysts expect that Allergan plc will post 16.27 EPS for the current year.

Allergan declared that its Board of Directors has initiated a stock repurchase plan on Monday, September 25th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the company to buy up to 2.8% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s board believes its stock is undervalued.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.watchlistnews.com/gofen-glossberg-llc-il-has-12-69-million-stake-in-allergan-plc-agn/1809065.html.

Allergan Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.